Logo

CUE

Cue Biopharma, Inc.

CUE

Cue Biopharma, Inc. • NASDAQ
$0.63 ▲ 0.67% (+0.00)
Market Cap $49.60 M
52w High $1.75
52w Low $0.54
Dividend Yield 0%
P/E -1.54
Volume 31.98K
Outstanding Shares 78.74M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $2.149M ▼ $9.614M ▼ $-7.448M ▲ -346.58% ▼ $-0.07 ▲ $-7.294M ▲
Q2-2025 $2.954M ▲ $11.589M ▼ $-8.482M ▲ -287.136% ▲ $-0.089 ▲ $-7.641M ▲
Q1-2025 $421K ▼ $12.72M ▲ $-12.257M ▼ -2.911K% ▼ $-0.17 ▼ $-11.247M ▼
Q4-2024 $1.576M ▼ $11.209M ▼ $-9.496M ▼ -602.538% ▼ $-0.13 ▲ $-9.245M ▼
Q3-2024 $3.336M $12.151M $-8.66M -259.592% $-0.17 $-7.595M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $18.672M ▼ $31.644M ▼ $18.398M ▼ $13.246M ▼
Q2-2025 $27.962M ▲ $40.707M ▲ $22.548M ▲ $18.159M ▲
Q1-2025 $13.136M ▼ $22.254M ▼ $15.674M ▲ $6.58M ▼
Q4-2024 $23.388M ▼ $32.191M ▼ $14.692M ▼ $17.499M ▼
Q3-2024 $32.42M $44.81M $19.444M $25.366M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-7.448M ▲ $-9.024M ▼ $-6.768M ▼ $1K ▼ $-15.791M ▼ $-9.024M ▼
Q2-2025 $-8.482M ▲ $-3.415M ▲ $-27K ▲ $17.798M ▲ $14.356M ▲ $-3.442M ▲
Q1-2025 $-12.257M ▼ $-8.172M ▲ $-150K ▼ $-1M ▼ $-9.322M ▲ $-8.322M ▲
Q4-2024 $-9.496M ▼ $-9.028M ▼ $-1K ▼ $-932K ▼ $-9.961M ▼ $-9.03M ▼
Q3-2024 $-8.66M $-7.527M $98K $9.821M $2.392M $-7.526M

Five-Year Company Overview

Income Statement

Income Statement Cue Biopharma is still very much a research-focused, pre-commercial company. Revenue has been tiny and irregular, mainly from collaborations rather than product sales. Operating costs, driven largely by R&D and overhead, have been consistently higher than income, leading to steady annual losses. The size of those losses has been fairly stable over the last several years, with a small improvement most recently, but the business is still far from break-even and remains reliant on external funding rather than internally generated profits.

Balance Sheet

Balance Sheet The balance sheet shows a gradual drawdown of resources over time. Total assets, and especially cash, have trended down as the company funds operations. Debt levels are relatively low, which limits financial strain from interest payments, but shareholders’ equity has also been shrinking as losses accumulate. In simple terms, the company still has a positive capital base, but its financial cushion is thinner than it was a few years ago.

Cash Flow

Cash Flow Cue Biopharma consistently spends more cash than it brings in. Operating cash outflows have been steady and negative, reflecting ongoing R&D and corporate expenses without offsetting product revenue. Free cash flow is similarly negative and closely tracks operating cash flow, since the company is not investing heavily in physical assets. This pattern means the business is burning cash at a fairly steady pace and will likely continue to depend on capital raises or partnership payments to fund its pipeline.

Competitive Edge

Competitive Edge Competitively, Cue sits in a crowded but high-potential area of immunotherapy, with a differentiated approach. Its Immuno-STAT and Neo-STAT platforms aim to modulate T cells in a more precise and potentially safer way than many existing immune therapies, which could be a meaningful advantage if clinical data continues to support the concept. Partnerships with large pharmaceutical companies add credibility and help extend its reach, but as a small, clinical-stage biotech, it faces significant competition from larger, better-funded players, and its position ultimately depends on the strength of its data and the quality of its collaborations.

Innovation and R&D

Innovation and R&D Innovation is the core of Cue Biopharma’s story. The company is building a modular platform that can be tuned to different cancers and autoimmune diseases by targeting specific T cells, which, in theory, allows for tailored and more controlled immune responses. The pipeline spans both oncology and autoimmunity, with a recent strategic pivot toward autoimmune indications while advancing cancer programs largely via partners. This approach is scientifically ambitious and potentially scalable, but it also carries typical early-stage biotech risks: heavy R&D spending, long timelines, and high uncertainty around clinical outcomes and regulatory success.

Summary

Overall, Cue Biopharma is an early-stage, science-driven biotech with a shrinking but still positive financial base, recurring operating losses, and ongoing cash burn. Its value proposition is almost entirely tied to the success of its Immuno-STAT and related platforms, plus the progress and terms of its partnerships. The company’s future hinges less on current financial performance and more on whether its clinical trials, autoimmune pivot, and collaboration strategy convert promising immunology concepts into approved therapies and meaningful commercial agreements.

NEWS

November 12, 2025 · 4:05 PM UTC

Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Read more

November 6, 2025 · 8:00 AM UTC

Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors

Read more

September 29, 2025 · 9:00 AM UTC

Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates

Read more